Demographic Characteristics and Outcomes of Patients With mrCDI Who Received a FDX-TP Regimen: The SFI After the Most Effective Prior Treatment Is Compared With the SFI After FDX-TP
| . | Age, Years/Sex . | No. of CDI Episodes . | Prior Regimens . | Additional Antimicrobial Exposure After the Last Prior Regimen . | Longest SFI for Non-FDX-TP Course, Days (Antibiotic) . | SFI Post FDX-TP, Days . | Recurrence After FDX-TP . | Additional Antimicrobial Exposure After FDX-TP Regimens . |
|---|---|---|---|---|---|---|---|---|
| Patient 4 | 68/F | 5 | M, M, VT, V + FDX-CH, FDX | None | 64 (VT) | 232 | No | None |
| Patient 5 | 46/F | 11 | M, V, V, VT, V + FMT, V, RC, VT, VT, VT + FDX-CH, FDX | None | 102 (V) | 462 | No | None |
| Patient 9 | 46/F | 3 | VT, FDX, FDX | None | 29 (FDX) | 571 | No | None |
| Patient 10 | 65/M | 4 | U, M + V, VT, VT | None | 21 (V) | 429 | No | None |
| Patient 11 | 37/F | 4 | M, M, VT, V + FDX | None | 15 (M) | 375 | No | None |
| Patient 12 | 54/F | 4 | M, V, VT | None | 35 (V) | 298 | No | None |
| Patient 13 | 68/F | 3 | M, VT, VT | None | 8 (M) | 121 | No | None |
| Patient 14 | 70/F | 4 | VT, VT, VT, VT | None | 81 (VT) | 79 | No | None |
| Patient 15* | 86/M | 8,9 | M,M,V,V,VT,V,VT,VT + FDX-TP,VT | None, Amoxicillin | 41 (V) | 282 | Yes, No | Yes |
| Patient 16 | 67/M | 5 | M,M,VT,V,VT | None | 17 (V) | 118 | Yes | Yes |
| Patient 17 | 66/M | 6 | U,M,M,V,VT, VT | None | 20 (V) | 0 | N/A** | None |
| Patient 18 | 91/M | 4 | M,M + VT,VT, VT | None | 9 (VT) | 23 | No | None |
| Mean ± SD: | 63.6 ± 16 | 5.1 ± 2 | Median (IQR) | 25 (30) | 257 (280)*** |
| . | Age, Years/Sex . | No. of CDI Episodes . | Prior Regimens . | Additional Antimicrobial Exposure After the Last Prior Regimen . | Longest SFI for Non-FDX-TP Course, Days (Antibiotic) . | SFI Post FDX-TP, Days . | Recurrence After FDX-TP . | Additional Antimicrobial Exposure After FDX-TP Regimens . |
|---|---|---|---|---|---|---|---|---|
| Patient 4 | 68/F | 5 | M, M, VT, V + FDX-CH, FDX | None | 64 (VT) | 232 | No | None |
| Patient 5 | 46/F | 11 | M, V, V, VT, V + FMT, V, RC, VT, VT, VT + FDX-CH, FDX | None | 102 (V) | 462 | No | None |
| Patient 9 | 46/F | 3 | VT, FDX, FDX | None | 29 (FDX) | 571 | No | None |
| Patient 10 | 65/M | 4 | U, M + V, VT, VT | None | 21 (V) | 429 | No | None |
| Patient 11 | 37/F | 4 | M, M, VT, V + FDX | None | 15 (M) | 375 | No | None |
| Patient 12 | 54/F | 4 | M, V, VT | None | 35 (V) | 298 | No | None |
| Patient 13 | 68/F | 3 | M, VT, VT | None | 8 (M) | 121 | No | None |
| Patient 14 | 70/F | 4 | VT, VT, VT, VT | None | 81 (VT) | 79 | No | None |
| Patient 15* | 86/M | 8,9 | M,M,V,V,VT,V,VT,VT + FDX-TP,VT | None, Amoxicillin | 41 (V) | 282 | Yes, No | Yes |
| Patient 16 | 67/M | 5 | M,M,VT,V,VT | None | 17 (V) | 118 | Yes | Yes |
| Patient 17 | 66/M | 6 | U,M,M,V,VT, VT | None | 20 (V) | 0 | N/A** | None |
| Patient 18 | 91/M | 4 | M,M + VT,VT, VT | None | 9 (VT) | 23 | No | None |
| Mean ± SD: | 63.6 ± 16 | 5.1 ± 2 | Median (IQR) | 25 (30) | 257 (280)*** |
Abbreviations: CDI, Clostridium difficile infection; FDX, standard fidaxomicin treatment regimen; FDX-CH, fidaxomicin chaser; FDX-TP, fidaxomicin taper; FMT, fecal microbiota transplantation; IQR, interquartile range; IVIG, intravenous immunoglobulin; M, metronidazole; mrCDI, multiple recurrent CDI; N/A, not applicable; RC, rifaximin chaser; SD, standard deviation; SFI, symptom-free interval; U, unknown; V, standard vancomycin treatment course; VT, vancomycin taper.
* Patient was given 2 FDX-TP courses.
** Patient did not complete FDX-TP regimen.
*** P = .003 compared with non-FDX-TP SFI, Mann–Whitney U test.
Demographic Characteristics and Outcomes of Patients With mrCDI Who Received a FDX-TP Regimen: The SFI After the Most Effective Prior Treatment Is Compared With the SFI After FDX-TP
| . | Age, Years/Sex . | No. of CDI Episodes . | Prior Regimens . | Additional Antimicrobial Exposure After the Last Prior Regimen . | Longest SFI for Non-FDX-TP Course, Days (Antibiotic) . | SFI Post FDX-TP, Days . | Recurrence After FDX-TP . | Additional Antimicrobial Exposure After FDX-TP Regimens . |
|---|---|---|---|---|---|---|---|---|
| Patient 4 | 68/F | 5 | M, M, VT, V + FDX-CH, FDX | None | 64 (VT) | 232 | No | None |
| Patient 5 | 46/F | 11 | M, V, V, VT, V + FMT, V, RC, VT, VT, VT + FDX-CH, FDX | None | 102 (V) | 462 | No | None |
| Patient 9 | 46/F | 3 | VT, FDX, FDX | None | 29 (FDX) | 571 | No | None |
| Patient 10 | 65/M | 4 | U, M + V, VT, VT | None | 21 (V) | 429 | No | None |
| Patient 11 | 37/F | 4 | M, M, VT, V + FDX | None | 15 (M) | 375 | No | None |
| Patient 12 | 54/F | 4 | M, V, VT | None | 35 (V) | 298 | No | None |
| Patient 13 | 68/F | 3 | M, VT, VT | None | 8 (M) | 121 | No | None |
| Patient 14 | 70/F | 4 | VT, VT, VT, VT | None | 81 (VT) | 79 | No | None |
| Patient 15* | 86/M | 8,9 | M,M,V,V,VT,V,VT,VT + FDX-TP,VT | None, Amoxicillin | 41 (V) | 282 | Yes, No | Yes |
| Patient 16 | 67/M | 5 | M,M,VT,V,VT | None | 17 (V) | 118 | Yes | Yes |
| Patient 17 | 66/M | 6 | U,M,M,V,VT, VT | None | 20 (V) | 0 | N/A** | None |
| Patient 18 | 91/M | 4 | M,M + VT,VT, VT | None | 9 (VT) | 23 | No | None |
| Mean ± SD: | 63.6 ± 16 | 5.1 ± 2 | Median (IQR) | 25 (30) | 257 (280)*** |
| . | Age, Years/Sex . | No. of CDI Episodes . | Prior Regimens . | Additional Antimicrobial Exposure After the Last Prior Regimen . | Longest SFI for Non-FDX-TP Course, Days (Antibiotic) . | SFI Post FDX-TP, Days . | Recurrence After FDX-TP . | Additional Antimicrobial Exposure After FDX-TP Regimens . |
|---|---|---|---|---|---|---|---|---|
| Patient 4 | 68/F | 5 | M, M, VT, V + FDX-CH, FDX | None | 64 (VT) | 232 | No | None |
| Patient 5 | 46/F | 11 | M, V, V, VT, V + FMT, V, RC, VT, VT, VT + FDX-CH, FDX | None | 102 (V) | 462 | No | None |
| Patient 9 | 46/F | 3 | VT, FDX, FDX | None | 29 (FDX) | 571 | No | None |
| Patient 10 | 65/M | 4 | U, M + V, VT, VT | None | 21 (V) | 429 | No | None |
| Patient 11 | 37/F | 4 | M, M, VT, V + FDX | None | 15 (M) | 375 | No | None |
| Patient 12 | 54/F | 4 | M, V, VT | None | 35 (V) | 298 | No | None |
| Patient 13 | 68/F | 3 | M, VT, VT | None | 8 (M) | 121 | No | None |
| Patient 14 | 70/F | 4 | VT, VT, VT, VT | None | 81 (VT) | 79 | No | None |
| Patient 15* | 86/M | 8,9 | M,M,V,V,VT,V,VT,VT + FDX-TP,VT | None, Amoxicillin | 41 (V) | 282 | Yes, No | Yes |
| Patient 16 | 67/M | 5 | M,M,VT,V,VT | None | 17 (V) | 118 | Yes | Yes |
| Patient 17 | 66/M | 6 | U,M,M,V,VT, VT | None | 20 (V) | 0 | N/A** | None |
| Patient 18 | 91/M | 4 | M,M + VT,VT, VT | None | 9 (VT) | 23 | No | None |
| Mean ± SD: | 63.6 ± 16 | 5.1 ± 2 | Median (IQR) | 25 (30) | 257 (280)*** |
Abbreviations: CDI, Clostridium difficile infection; FDX, standard fidaxomicin treatment regimen; FDX-CH, fidaxomicin chaser; FDX-TP, fidaxomicin taper; FMT, fecal microbiota transplantation; IQR, interquartile range; IVIG, intravenous immunoglobulin; M, metronidazole; mrCDI, multiple recurrent CDI; N/A, not applicable; RC, rifaximin chaser; SD, standard deviation; SFI, symptom-free interval; U, unknown; V, standard vancomycin treatment course; VT, vancomycin taper.
* Patient was given 2 FDX-TP courses.
** Patient did not complete FDX-TP regimen.
*** P = .003 compared with non-FDX-TP SFI, Mann–Whitney U test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
